Thus, MR30 is a multifaceted molecule, which can be used under multiple contexts: (a) to exert selectivity for the HER family of oncogenes, (b) to induce potent growth inhibition in tumour cells with PTEN, K-RAS, B-RAF mutations and (c) to sensitize tumours that co-express EGFR and MGMT to TMZ. Here, KRAS is linked to neoplasm.